구성원

구성원

Ha Jung-mi 하정미 교수

  • DepartmentDepartmentProf. Dept. of Pharmacy, College of PharmacyFinal degree : Ph.D. in ~ ( ~Univ.) / Professor
  • E-mailE-mailjhah@hanyang.ac.kr
  • Office PhoneOffice Phone031-400-5803
  • HomepageHomepagehttps://jhah.hanyang.ac.kr/?lang=us
  • 학과/직책학과/직책약학 대학 약학과 / 교수
  • 이메일이메일jhah@hanyang.ac.kr
  • 전화번호전화번호031-400-5803
  • 홈페이지홈페이지https://jhah.hanyang.ac.kr/
Research Keywords
연구키워드
  • #TargetDiscovery #Drug Design #Lead Discovery #SAR #Lead Optimization #Drug Candidate #Protein Kinase #Targeted Anticancer agent #Therapeutics for Neurodegenerative Disease #Oral Immune Anticancer agent
  • #타겟 디스커버리 #저분자 약물 설계 # 리드 디스커버리 #SAR #리드최적화 #후보 물질 발굴 #단백질인산화효소 # 표적 항암제 #퇴행성 뇌질환 치료
Research Objectives
연구목표
  • Establishment of Protein Kinase-focused Compound Library
  • Target Structure based Drug Design and Discovery
  • Synthesis of designed compound analogs and Lead Discovery
  • Drug Candidate Discovery through SAR-Optimization
  • Drug Development through structural optimization
  • 타겟 군 중심의 화합물 라이브러리 확보
  • 타겟의 구조에 따른 저분자 약물 설계 (Structure based Drug Discovery)
  • 설계된 화합물군의 신속한 합성을 통한 Lead Discovery
  • 확보한 Lead 중심의 SAR-Optimization 을 통한 후보물질 확보
  • 후보 물질의 약물성 획득을 위한 최적화
Brief Research Experience
주요경력
  • Professor, Hanyang University (2010년~present)
  • Research Scientist, Korea Institute of Science and Technology (2007~2010)
  • Publication > 55
  • PCT, WO, KP >30
  • Tech transfer 1, Knowhow transfer 1
  • Fragment based Ligand Discovery : Platform Technology
  • Development of protein kinase inhibitors as anticancer agent and therapeutics for neurodegenerative diseases
  • Development of therapeutics for Proteinopathy
  • Funding sources:

    National Research Foundation of Korea/our research center

    BK21 Four research center/University Focused Research Center for Proteinopathy

  • 교수, 한양대학교 약학과 (2010년~현재)
  • 선임 연구원, 한국과학기술연구원(KIST 2007~2010년)
  • 논문 편수: 55편, 국제특허와 국내 특허 등록 다수
  • 기술 이전 1건, Knowhow 이전 1건
  • Fragment based Ligand Discovery : Platform 기술 확보
  • 구조 기반 설계에 Protein Kinase의 저해제 설계 및 합성 : 항암제/퇴행성 뇌질환 치료제로서 개발 연구
  • Proteinopathy 질환 중심의 분자 타겟 발굴
  • 수행과제 지원 기관:

    과학 기술부 : 바이오 의료 기술 개발 사업/ 중견 연구자 지원 사업/ 여성 연구자 사업

    교육부 : 이공계 대학 중점 연구소 / BK21FOUR 사업단

Thesis
논문
  • 1. “Carbamate JNK3 Inhibitors Show Promise as Effective Treatments for Alzheimer's Disease: In Vivo Studies on Mouse Models” Joonhong Jun, Hyungwoo Moon, Songyi Yang et alJung-Mi HahJournal of Medicinal Chemistry2023, in press.
  • 2. “Discovery of novel imidazole chemotypes as isoform-selective JNK3 inhibitors for the treatment of Alzheimer's disease” Joonhong Jun, Songyi Yang et alJung-Mi HahEuropean Journal of Medicinal Chemistry2023,245 (1), 114984-114913.
  • 3. “Novel 1,4,5,6-tetrahydrocyclopenta[d]imidazole-5-carboxamide-based JNK3 inhibitors: Design, synthesis, molecular docking, and therapeutic potential in neurodegenerative diseases” JoonhongJun, Jihyun Baek et alJung-Mi HahEuropean Journal of Medicinal Chemistry2023,245 (1), 114917-114931.
  • 4. “Design and Synthesis of Aminopyrimidinyl Pyrazole Analogs as PLK1 Inhibitors Using Hybrid 3D-QSAR and Molecular Docking” Swapnil P.Bhuzbal, Hyejin Kim, Hyunah Bae,Jung-Mi HahPharmaceuticals2022,15,1170-1184.
  • 5.“Rational design and synthesis of 2-(1H-indazol-6- yl)-1H-benzo[d]imidazole derivatives as inhibitors targeting FMS-like tyrosine kinase 3 (FLT3) and its mutants” Daseul Im, Joonhong Jun, Jihyun Baek,Hyejin Kim, Dahyun Kang, Hyunah Bae,Hyunwook Cho,Jung-Mi HahJournal of Enzyme inhibition and Med. Chem.2022,37(1),472-486.
  • 6. “A Perspective on the Development of c-Jun N-terminal Kinase Inhibitors as Therapeutics for Alzheimer's Disease: Investigating Structure through Docking Studies” Hyunwook Cho,Jung-Mi HahBiomedicine2021,9(10),1431-1443.
  • 7. “Discovery of 3-alkyl-5-aryl-1-pyrimidyl-1H-pyrazole derivatives as a novel selective inhibitor scaffold of JNK3” Youri Oh, Miyoung Jang, Songyi Yang, Hyungwoo Moon, Hyunwook Cho, Daseul Im,Jung-Mi HahJournal of Enzyme inhibition and Med. Chem.2020,35,372-376.
  • 8. “Nec-1 alleviates cognitive impairment with reduction of A and tau abnormalities in APP/PS1 mice” Seung-Hoon Yang, Dongkeun Kenneth Lee, Jisu Shin, Sejin Lee, Seungyeop Baek, Jiyoon Kim, Hoyong Jung, Jung-Mi Hah & Young Soo Kim,EMBO Mole. Med.2017,9 (1), 61-77
  • 9. “Discovery of 4-arylamido 3-methyl isoxazole derivatives as novel FMS kinase inhibitors” Daseul Im, Kyungjin Jung, Songyi Yang, Waqar Aman,Jung-Mi HahEuropean Journal of Medicinal Chemistry2015,102, 600-610.
  • 10. “De NovoDesign and Synthesis of a γ-Turn Peptidomimetic Scaffold and Its Application as JNK3 Allosteric Ligand” Mi-Hyun Kim, Junghun Lee,Jung-Mi HahChemistry An Asian Journal2015,10,1318-1326.
Research Topics
연구내용

목록으로